Case report: Curative effect and mechanism of surufatinib combined with toripalimab in the treatment of 1 case of lung large-cell neuroendocrine carcinoma
{{output}}
Background: Large-cell neuroendocrine lung carcinoma (LCNEC) is a rare heterogeneous tumour with rates ranging from 2.1% to 3.5%. The overall prognosis of pulmonary LCNEC is poor, and the 5-year overall survival rate is only 21%.... ...
